In this expert perspective from Hawaiian Eye 2025, W. Lloyd Clark, MD, discusses the use of aflibercept 8 mg in the treatment of retinal vein occlusion.
In this expert perspective from Hawaiian Eye 2025, Ashkan M. Abbey, MD, discusses an advancement in retinal vein occlusion treatment from 2024 and highlights a treatment in the pipeline for 2025.
(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in ...
GlobalData on MSN21h
J&J sues Samsung Bioepis over ‘surreptitious’ breach of Stelara biosimilar contractSamsung Bioepis has now allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission ...
Retinal gene therapy advancements may rewrite the book on treatments for age-related macular degeneration and diabetic eye diseases.
The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback